Mirikizumab IV + Mirikizumab SC + Vedolizumab IV + Placebo IV + Placebo SC
Phase 3Withdrawn 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Ulcerative Colitis
Conditions
Ulcerative Colitis
Trial Timeline
Apr 20, 2021 → Jun 5, 2024
NCT ID
NCT04469062About Mirikizumab IV + Mirikizumab SC + Vedolizumab IV + Placebo IV + Placebo SC
Mirikizumab IV + Mirikizumab SC + Vedolizumab IV + Placebo IV + Placebo SC is a phase 3 stage product being developed by Eli Lilly for Ulcerative Colitis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04469062. Target conditions include Ulcerative Colitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04469062 | Phase 3 | Withdrawn |
Competing Products
20 competing products in Ulcerative Colitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Mirikizumab SC + Mirikizumab IV + Placebo SC | Eli Lilly | Phase 3 | 77 |
| Mirikizumab | Eli Lilly | Phase 2 | 52 |
| Azathioprine + Placebo | Celltrion | Approved | 85 |
| CT-P13 SC (Infliximab) | Celltrion | Phase 3 | 77 |
| Afimkibart + Placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| Tacrolimus | Astellas Pharma | Phase 3 | 77 |
| tacrolimus + Placebo | Astellas Pharma | Phase 3 | 77 |
| Filgotinib Maleate | Eisai | Approved | 85 |
| AJM300 + Placebo | Eisai | Phase 3 | 77 |
| GSK3050002 + Placebo | Eisai | Phase 1 | 33 |
| adalimumab + placebo | Eisai | Phase 3 | 77 |
| E6007 + Placebo | Eisai | Phase 2 | 52 |
| KHK4083 + Placebo | Kyowa Kirin | Phase 2 | 52 |
| KHK4083 + Placebo | Kyowa Kirin | Phase 1 | 33 |
| Arm1 + Arm 2 | Zydus Lifesciences | Phase 2 | 52 |
| Mirikizumab + Mirikizumab | Eli Lilly | Phase 3 | 77 |
| LY3471851 + Placebo | Eli Lilly | Phase 2 | 52 |
| Mirikizumab + Placebo | Eli Lilly | Phase 2 | 52 |
| LY4268989 + Placebo | Eli Lilly | Phase 2 | 52 |
| Eltrekibart + Mirikizumab + Placebo | Eli Lilly | Phase 2 | 52 |